INMED PHARMACEUTICALS INC (INM:NASDAQ)
$1.36 0.03 (2.2556%)
Analysed INMED PHARMACEUTICALS INC (INM:NASDAQ) News Sources
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
22-07-2026
yahoo.com
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
09-09-2026
yahoo.com
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
18-09-2026
yahoo.com
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
06-05-2026
yahoo.com
A migraine drugmaker heads to the public markets through reverse merger
19-05-2026
biopharmadive.com
InMed Pharmaceuticals Amends Preferred Investment Options
19-05-2026
yahoo.com
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
19-05-2026
advfn.com
/C O R R E C T I O N -- InMed Pharmaceuticals/
20-05-2026
yahoo.com
INM Stock Alert: What to Know as InMed, Mentari Announce Merger
20-05-2026
barchart.com
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
04-06-2026
yahoo.com
What is the current price of INMED PHARMACEUTICALS INC (INM:NASDAQ)?
The current price of INMED PHARMACEUTICALS INC (INM:NASDAQ) is $1.36.
INMED PHARMACEUTICALS INC (INM:NASDAQ) absolute price change since previous trading day?
The absolute price change of INMED PHARMACEUTICALS INC (INM:NASDAQ) since the previous trading day is $0.03.
INMED PHARMACEUTICALS INC (INM:NASDAQ) percentage price change since previous trading day?
The percentage price change of INMED PHARMACEUTICALS INC (INM:NASDAQ) since the previous trading day is 2.2556%.
What is the most recent average sentiment score for INMED PHARMACEUTICALS INC (INM:NASDAQ)?
The most recent average sentiment score for INMED PHARMACEUTICALS INC (INM:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for INMED PHARMACEUTICALS INC (INM:NASDAQ)?
The most recent sentiment for INMED PHARMACEUTICALS INC (INM:NASDAQ) is .
SEC-8K** Filing Available For INMED PHARMACEUTICALS INC (INM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.